Abstract
BackgroundTuberculosis (TB) is a major global health problem and has replaced HIV as the leading cause of death from a single infectious agent.MethodsHere, we applied high throughput sequencing to study the immune repertoire of nine pulmonary tuberculosis patients and nine healthy control samples.ResultsTuberculosis patients and healthy controls displayed significantly different high express clones and distinguishable sharing of CDR3 sequences. The TRBV and TRBJ gene usage showed higher expression clones in patients than in controls and we also found specific high express TRBV and TRBJ gene clones in different groups. In addition, six highly expressed TRBV/TRBJ combinations were detected in the CD4 group, 21 in the CD8 group and 32 in the tissue group.ConclusionIn conclusion, we studied the patients with tuberculosis as well as healthy control individuals in order to understand the characteristics of immune repertoire. Sharing of CDR3 sequences and differential expression of genes was found among the patients with tuberculosis which could be used for the development of potential vaccine and targets treatment.
Highlights
Tuberculosis (TB) is a major global health problem and has replacedHIV as the leading cause of death from a single infectious agent
Tuberculosis is a disease caused by mycobacterium tuberculosis infection
In the tuberculosis patient group, there were six TRBV/TRBJ combinations which were used more than 0.5% in CD4 group, and 21 high expression
Summary
Commission of Shenzhen (HTP study of sarcoidosis TCRß chain CDR3 immune repertoire, JCYJ20160422142121988), Science and Technology Department of Guangdong province, (Kartagener syndrome pathogenic gene diagnosis and microarray diagnosis kit, 2017A020214016s), Science and Technology Commission of Shenzhen (identification of gene mutation sites of genetic pathogenic genes in pulmonary embolism and diagnosis panel design, JCYJ20170413093032806), Key. Laboratory of respiratory diseases in Shenzhen (ZDSYS201504301616234)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
